PEG-sTNF-RI. Amgen.
PEGylated soluble tumor necrosis factor-receptor type I (PEG-sTNF-RI) is a second-generation TNF-binding protein in development by Amgen as a potential treatment for rheumatoid arthritis (RA). PEG-sTNF-RI is an optimized, monomeric form of the first-generation molecule, TNFbp. By 1999, PEG-sTNF-RI was undergoing phase II trials for RA, and these trials were ongoing in March 2003.